ARID5B influences anti-metabolite drug sensitivity and prognosis of acute lymphoblastic leukemia.

CONCLUSIONS: Our data indicates that ARID5B is an important molecular determinant of antimetabolite drug sensitivity in ALL, in part through p21-mediated effects on cell-cycle progression.
PMID: 31573954 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 30, 2019 Category: Cancer & Oncology Authors: Yang JJ, Xu H, Zhao X, Bhojwani D, E S, Goodings C, Zhang H, Seibel NL, Yang W, Li C, Carroll WL, Evans WE Tags: Clin Cancer Res Source Type: research